in the ACCORD study, and 6.9% in the VADT study) delayed the progression of albuminuria, but had no significant effect on the rates of other microvascular complications or cardiovascular mortality. In fact, the ACCORD study was terminated early after 3.7 years because of increased cardiovascular and all-cause mortality in the intensive glycemic therapy group. Nevertheless, these last findings must be interpreted with caution as overestimation of harm by chance in truncated trials can lead to misleading conclusions.
6
Should we aim for an intensive glycemic control (ie, HbA 1c ≤6.5%) in patients with long-standing type 2 diabetes and at risk for cardiovascular disease? The results from the ADVANCE, ACCORD, and VADT trials suggest that this strategy is not justified, as the renal benefit appears to be small, and no other significant improvements in patient-important outcomes were evident. Intensive glycemic control can lead to higher risk of hypoglycemia, and potentially also to escalation of costs and burden of treatment, as more medications will be required to achieve these tight glycemic targets. It should be noted, however, that in none of these studies the control arms had very poorly controlled diabetes (eg, mean HbA 1c levels >9%), and therefore the effect of standard glycemic management versus clearly poor control on long-term complications cannot be inferred from them. Also, because of the heterogeneity of interventions used to achieve intensive glycemic control, the ADVANCE, ACCORD, and VADT trials are not useful to dissect the individual benefits and harms of the different glucose-lowering medications that were used. Furthermore, heterogeneity of cointerventions may also have affected the results of some outcomes (eg, different antihypertensive treatments could have different effects on the progression of diabetic nephropathy).
Should we aim for a tighter glycemic control in younger patients (eg, age <55 years) with
The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial 1 sought to assess the effect of intensive glycemic control and the use of antihypertensive medications in patients over 55 years of age with type 2 diabetes and a history of major macrovascular or microvascular disease, or at least 1 other risk factor for vascular disease. Participants in the intensive glycemic control group followed a treatment strategy that used gliclazide and other glucose lowering medications-including insulin-targeting a glycated hemoglobin (HbA 1c ) level of 6.5% or lower. After a median follow-up of 5 years, the mean HbA 1c values were 6.5% in the intensive glycemic control group and 7.3% in the standard control group. ADVANCE showed a reduction in the development of albuminuria, but no changes in the incidence of severe nephropathy, retinopathy, or macrovascular events. The 5-year posttrial follow-up of the ADVANCE study, called ADVANCE-ON, 2 has recently been published. After a posttrial follow-up of almost 6 years, ADVANCE-ON failed to find favorable results in the risk of major macrovascular events or death from any cause with intensive glycemic control. The need for renal replacement therapy was reduced, but relatively few events were recorded raising concerns for imprecision.
The results of ADVANCE and ADVANCE-ON are, in several aspects, consistent with the findings from the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACCORD) and Veterans Affairs Diabetes Trial (VADT) trials.
3-5 These two studies also evaluated the effects of intensive glucose control in patients with long-standing type 2 diabetes and at high risk for cardiovascular disease. Compared with standard therapy (HbA 1c levels of 7.5% in the ACCORD study, and 8.4% in the VADT study), the use of intensive therapy (HbA 1c levels of 6.4%
